<DOC>
	<DOCNO>NCT00127842</DOCNO>
	<brief_summary>The overall objective study describe long-term effectiveness safety etanercept patient psoriatic arthritis Canadian clinical practice setting .</brief_summary>
	<brief_title>REPArE : Rating Evaluations Psoriatic Arthritis ( PsA ) With Etanercept ( Enbrel® )</brief_title>
	<detailed_description />
	<mesh_term>Arthritis</mesh_term>
	<mesh_term>Arthritis , Psoriatic</mesh_term>
	<mesh_term>Etanercept</mesh_term>
	<criteria>Presence psoriasis previous evidence psoriasis document dermatologist part usual care At least one follow form psoriatic arthritis ( PsA ) : Distal interphalangeal ( DIP ) involvement ( inflammatory ) Polyarticular arthritis , absence rheumatoid nodule presence psoriasis Arthritis mutilans Asymmetric peripheral arthritis Spinal involvement Active psoriatic arthritis time study enrollment Patients must demonstrate great 3 swollen joint great 3 tender/painful joint Greater 18 year age time consent Able start etanercept therapy per approve product monograph Informed consent must provide study specific procedure perform Active infection time initiate Enbrel® therapy Evidence skin condition ( e.g. , eczema ) psoriasis would interfere evaluation study medication A malignancy , basal cell carcinoma skin , situ carcinoma cervix , within past 5 year Known hypersensitivity etanercept component Patients receive , receive : Remicade® ( infliximab ) previous 3 month Humira® ( adalimumab ) previous 3 month Kineret® ( anakinra ) previous 15 day Patients receive receive etanercept Treatment investigational therapy 30 day prior enrollment study Active guttate , erythrodermic pustular psoriasis time screen Presence significant uncontrolled medical condition , Investigator 's opinion , precludes use etanercept outlined product monograph Sepsis risk septic syndrome Patients available followup assessment Concerns subject 's compliance protocol procedure</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>Psoriatic Arthritis</keyword>
	<keyword>PsA</keyword>
	<keyword>Commercial product</keyword>
	<keyword>American College Rheumatology</keyword>
	<keyword>ACR/PASI</keyword>
</DOC>